Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone LymphomaCamilla Mazzoni, Pier Luigi Zinzani, Pierluca Maglio et al.|European Journal Of Haematology|2024Cited by 3
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world studyBeatrice Casadei, Pier Luigi Zinzani, Lisa Argnani et al.|Blood Advances|2025Cited by 2
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practiceCinzia Pellegrini, Pier Luigi Zinzani, Beatrice Casadei et al.|Annals of Hematology|2025Cited by 2
Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future PotentialPier Luigi Zinzani, Alessandro Broccoli, Lisa Argnani et al.|Blood|2024Cited by 0
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapyMarianna Gentilini, Pier Luigi Zinzani, Beatrice Casadei et al.|Annals of Hematology|2025Cited by 0